Literature DB >> 8885002

IgA immune response against the mycobacterial antigen A60 in patients with active pulmonary tuberculosis.

M Alifano1, M Sofia, M Mormile, A Micco, A F Mormile, M Del Pezzo, L Carratù.   

Abstract

Searching for IgG and IgM against the mycobacterial antigen A60 has been recognized as a potential diagnostic tool for pulmonary tuberculosis. The role of detection of anti-A60 IgA in improving diagnostic accuracy of serology is not well known. In this study we measured with ELISA serum levels of both anti-A60 IgG and IgA in 216 subjects. 88 healthy volunteers (44 PPD- and 44 PPD+), 44 patients suffering from nontuberculous lung disease and 15 subjects with healed pulmonary tuberculosis constituted the control population; 69 patients with active pulmonary tuberculosis (35 cavitary forms, 26 productive forms and 8 miliary forms) were examined. The sensitivity of IgG test was 73.9% in pulmonary tuberculosis (77.1% in cavitary forms, 65.4% in productive forms, 87.5% in miliary forms); the specificity of the test was 95.9%. For the IgA test we observed a sensitivity of 72.5% (74.3 in cavitary forms, 69.2% in productive forms, 75.0 in miliary forms) and a specificity of 93.9%. Combination of the two tests increased the sensitivity to 84.0% (+10.1% compared to IgG test, +11.5% compared to IgA test); the specificity decreased to 92.5% (-3.4% vs. IgG test; -1.4 vs. IgA test). In conclusion, the combined use of evaluation of anti-A60 IgG and IgA increases the accuracy of serological diagnosis of pulmonary tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885002     DOI: 10.1159/000196563

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  8 in total

1.  Be alert to tuberculosis-mediated glomerulonephritis: a retrospective study.

Authors:  L Sun; Q Yuan; J Feng; L Yao; Q Fan; J Ma; L Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-07       Impact factor: 3.267

2.  Detection of IgG and IgA against the mycobacterial antigen A60 in patients with extrapulmonary tuberculosis.

Authors:  M Alifano; R De Pascalis; M Sofia; S Faraone; M Del Pezzo; I Covelli
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

3.  Lupus vulgaris with tubercular lymphadenitis and IgA nephropathy.

Authors:  Ambar Khaira; Om P Rathi; Sandeep Mahajan; Alok Sharma; Amit K Dinda; Suresh C Tiwari
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

4.  Rare association of cutaneous vasculitis, IgA nephropathy and antiphospholipid antibody syndrome with tuberculous lymphadenitis.

Authors:  Roberto Bueno Filho; Alberto Pinto Cordeiro; Flavia Tremeschin de Almeida; Catarina Shaletich; Roberto Silva Costa; Ana Maria F Roselino
Journal:  Clinics (Sao Paulo)       Date:  2012-12       Impact factor: 2.365

Review 5.  Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis.

Authors:  Karen R Steingart; Laura L Flores; Nandini Dendukuri; Ian Schiller; Suman Laal; Andrew Ramsay; Philip C Hopewell; Madhukar Pai
Journal:  PLoS Med       Date:  2011-08-09       Impact factor: 11.069

6.  Antibody Subclass and Glycosylation Shift Following Effective TB Treatment.

Authors:  Patricia S Grace; Sepideh Dolatshahi; Lenette L Lu; Adam Cain; Fabrizio Palmieri; Linda Petrone; Sarah M Fortune; Tom H M Ottenhoff; Douglas A Lauffenburger; Delia Goletti; Simone A Joosten; Galit Alter
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

Review 7.  Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review.

Authors:  Karen R Steingart; Megan Henry; Suman Laal; Philip C Hopewell; Andrew Ramsay; Dick Menzies; Jane Cunningham; Karin Weldingh; Madhukar Pai
Journal:  PLoS Med       Date:  2007-06       Impact factor: 11.069

Review 8.  Tuberculosis-associated IgA nephropathy.

Authors:  Yamei Wang; Yuhong Tao
Journal:  J Int Med Res       Date:  2018-06-04       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.